The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy

American Journal of Health-System Pharmacy

Volumn 56, Issue 6, 1999, Pages 525-536

  Lewis, Russell E ^a   Klepser, Michael E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Amphotericin B; Antifungals; Candida species; Candidiasis; Combined therapy; Cytokines; Echinocandins; Epidemiology; Liposomes; Resistance; SCH56592; Vo riconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; POSACONAZOLE; VORICONAZOLE; CASPOFUNGIN; CYTOKINE; ECHINOCANDIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; HOSPITAL INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FORMULATION; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY;

EID: 0033106434     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.6.525     Document Type: Review

References (90)

1. Centers for Disease Control and Prevention. Advance report of final mortality statistics, 1989. Mon Vital Stat Rep. 1992; 40:1-13.
2. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States 1980-1989. Am J Med. 1991; 91(suppl 3B):86S-9S.
3. Jones RN, Marshall SA, Pfaller MA et al. Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis. 1997; 29:95-102.
4. Jarvis WR. Epidemiology of nosocomial fungal infections with an emphasis on Candida species. Clin Infect Dis. 1995; 20:1526-30.
5. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis. 1996; 22(suppl 2):S89-94.
6. Demuri GP, Hostetter MK. Resistance to antifungal agents. Pediatr Clin North Am. 1995; 42:665-85.
7. Edwards JE Jr, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997; 25:43-59.
8. Pittet D, Li N, Woolson RF et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis. 1997; 24:1068-78.
9. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Meci. 1988; 148:2642-5.
10. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med. 1993; 119:270-2.
11. Miller PJ, Wenzel RP. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections. J Infect Dis. 1987; 156:471-7.
12. Edwards JE Jr, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. Clin Infect Dis. 1992; 14(suppl 1):S106-13.
13. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis. 1995; 20:1531-4.
14. Nguyen MH, Peacock JE Jr, Morris AJ et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100:617-23.
15. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994; 38:1422-7.
16. Rex JH, Pfaller MA, Barry AL et al. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother. 1995; 39:40-4.
17. Rex JH, Pfaller MA, Galgiani JN et al., for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vivo-in vitro correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis. 1997; 24:235-47.
18. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1997; 41:233-5.
19. Nguyen MH, Clancy CJ, Yu VL et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect. 1998; 177:425-30.
20. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995; 20:115-25.
21. Abi-Said D, Anaissie E, Uzun O et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997; 24:1122-8.
22. White MH. Editorial response: the contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis. 1997; 24:1129-30.
23. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
24. Pfaller MA, Bale M, Buschelman B et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995; 33:1104-7.
25. Rex JH, Pfaller MA, Lancaster M et al. Quality control guidelines for National Committee for Clinical Laboratory Standards - recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol. 1996; 34:816-7.
26. Grant SM, Clissold SP. Fluconazole: review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycosis. Drugs. 1990; 39:877-916.
27. Diflucan package insert. Groton, CT: Pfizer-Roerig; 1996 May.
28. Sporonox oral solution package insert. Piscataway, NJ: Janssen; 1997 Feb.
29. Arikan S, Akova M, Hayran M et al. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis. 1998; 26:903-8.
30. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol. 1989; 27:236-40.
31. Sanchez V, Vazquez JA, Barth-Jones D et al. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med. 1993; 94:577-82.
32. Goldman M, Pottage JC Jr, Weaver DC. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore). 1993; 72:143-50.
33. Aisner J, Schimpff SC, Sutherland JC et al. Torulopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization. Am J Med. 1976; 61:23-8.
34. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis. 1992; 14:756-66.
35. Hadfield TL, Smith MB, Winn RE et al. Mycoses caused by Candida lusitaniae. Rev Infect Dis. 1987; 9:1006-12.
36. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991; 325:1274-7.
37. Wingard JR, Merz WG, Rinaldi MG et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993; 37:1847-9.
38. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1979; 16:123-6.
39. Notario V, Gale EF, Kerridge D et al. Phenotypic resistance to amphotericin B in Candida albicans: relationship to glucan metabolism. J Gen Microbiol. 1982; 128:761-7.
40. Safe LM, Safe SH, Subden RE et al. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol. 1977; 23:398-401.
41. Sokol-Anderson M, Sligh JE Jr, Elberg S et al. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother. 1988; 32:702-5.
42. Howell SA, Mallet AI, Noble WC. A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains. J Appl Bacteriol. 1990; 69:692-6.
43. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol. 1986; 132:2421-31.
44. Vanden Bossche H, Marichal P, Odds F. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992; 36:2602-10.
45. Wheat J, Marichal P, Vanden Bossche H et al. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother. 1997; 41:410-4.
46. Hitchcock CA, Pye GW, Troke PF. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993; 37:1962-5.
47. Venkateswarlu K, Denning DW, Manning NJ et al. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother. 1996; 40:2443-6.
48. Albertson GD, Niimi M, Cannon RD et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother. 1996; 40:2835-41.
49. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother. 1995; 39:1696-9.
50. Sanglard D, Kuchler K, Ischer F et al. Mechanisms of resistance to azole antifungal agents in Candida albikans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995; 39:2378-86.
51. r gene. Antimicrob Agents Chemother. 1995; 39:422-6.
52. Chavanet P, Lopez J, Grappin M. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS. 1994; 8:945-50.
53. Maenza JR, Merz WG, Romagnoli MJ et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis. 1997; 24:28-34.
54. Millon L, Manteaux A, Reboux G et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol. 1994; 32:1115-8.
55. Newman SL, Flanigan TP, Fisher A et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994; 19:684-6.
56. Redding S, Smith J, Farnacci G et al. Resistance of Candida albicans to fluconazole during the treatment of oropharyngeal candidiasis in a patient with AIDS. Clin Infect Dis. 1994; 18:240-2.
57. Chryssanthou E, Torssander J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis. 1995; 27:391-5.
58. Pfaller MA, Rhine-Chalberg J, Redding SW et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 1994; 32:59-64.
59. Quereda C, Polanco AM, Giner C et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996; 15:30-7.
60. Ruhnke M, Eigler A, Tennasenn I. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidiasis and human immunodeficiency syndrome. J Clin Microbiol. 1994; 32:2092-8.
61. Denning DW. Can we prevent azole resistance in fungi? Lancet. 1995; 346:454-5.
62. Warren NG, Hazen KC. Candida, Cryptococcus and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA et al., eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology; 1995.
63. Scheven M, Jünemann K, Schramm H et al. Successful treatment of Candida albicans sepsis with a combination of flucytosine and fluconazole. Mycoses. 1992; 35:315-6.
64. Barbaro G, Barbarini G, Di Lorenzo G et al. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. Chest. 1996; 110: 1507-14.
65. Abele-Horn M, Kopp A, Sternberg U et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection. 1996; 24:426-32.
66. Pfaller MA, Housten A, Coffman S. Application of CHROMagar Candida for rapid screening of clinical specimens of Candida albicans, Candida tropicalis, Candida krusei, and Candida glabrata. J Clin Microbiol. 1996; 34:58-61.
67. Colombo AL, Barchiesi F, McGough DA et al. Comparison of Etest and National Committee for Clinical Laboratory Standards broth microdilution method for azole antifungal susceptibility testing. J Clin Microbiol. 1995; 33:535-40.
68. Sugar AM, Hitchcock CA, Troke PF et al. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother. 1995; 39:598-601.
69. Martin E, Mair F, Bhakdi S. Antagonistic effects of fluconazole and flucytosine on candidicidal action of amphotericin B in human serum. Antimicrob Agents Chemother. 1994; 38:1331-8.
70. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother. 1995; 39: 1907-12.
71. Klepser ME, Wolfe EJ, Jones RN et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother. 1997; 41:1392-5.
72. Atkinson BA, Bocanegra R, Colombo AL et al. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. Antimicrob Agents Chemother. 1994; 38:1604-7.
73. Sugar AM, Salibian M, Goldani LZ. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother. 1994; 38: 371-3.
74. Lewis RE, Lund BC, Klepser ME et al. Assessment of the anti-fungal activity of fluconazole and amphotericin B administered alone, and in combination against Candida albicans using a dynamic in vitro infection model. Antimicrob Agents Chemother. 1998; 42:1382-6.
75. Anaisse EJ, Darouiche RO, Abi-Said D et al. Management of invasive Candida infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996; 23:964-72.
76. Rex JH, Bennet JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994; 331:1325-30.
77. Venkateswarlu K, Denning DW, Kelly SL. Inhibition and interaction of cytochrome P450 of Candida krusei with azole anti-fungal drugs. J Med Vet Mycol. 1997; 35:19-25.
78. Hiemnez JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996; 22(suppl2):S133-44.
79. Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother. 1997; 31:1174-86.
80. Anaisse EJ, White M, Uzin O et al. Amphotericin B lipid complex (Abelcet) versus amphotericin B for the treatment of hematogenous candidiasis and invasive candidiasis: a prospective randomized clinical trial. Paper presented at 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL; 1994 Oct 1.
81. Walsh T, Bodensteiner D, Hiemnez J et al. A randomized double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario; 1997 Sep 29.
82. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol. 1994; 12:2471-508.
83. Freifeld A, Pizzo P. Colony-stimulating factors and neutropenia: intersection of data and clinical relevance. J Natl Cancer Inst. 1995; 87:781-2.
84. McGuinnis MR, Pasarell L, Sutton DA et al. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 1997; 41:1832-4.
85. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 1997; 41:13-6.
86. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997; 41:841-3.
87. Cacciapuoti A, Parmegiani R, Loebenberg D et al. Efficacy of SCH 56592 in pulmonary aspergillus and systemic candidiasis in mice. Paper presented at 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 18.
88. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994; 48:471-97.
89. Kurtz MB, Douglas C, Marrinan J et al. Increased antifungal activity of L-733,560, a water soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother. 1994; 38:2750-7.
90. Sable CA, Villanueva A, Arathon E et al. A randomized, double blind, multicenter trial of MK-991 (L-743,872) vs. amphotericin B (AmB) in the treatment of Candida esophagitis in adults. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario; 1997 Oct 1.